我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 强生
相关临床试验
0
0 进行中
药物批准
41
批准总数
监管机构
3
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
NMPA
National Medical Products Administration
5
FDA
Food and Drug Administration
35
SFDA
Saudi Food and Drug Authority
1
- The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025. - Nine drugs from major manufacturers including Bristol Myers Squibb's Eliquis, Novo Nordisk's Novolog, and Janssen's Stelara will be included in the voluntary rebate program. - The pilot program allows drugmakers to provide 340B discounted pricing through a rebate model rather than upfront discounts, with HRSA planning to evaluate the program for at least one year. - The initiative follows legal challenges from Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly regarding HRSA's authority to review and approve rebate models in the 340B program.
